| This report contains COVID-19 specific updates.
Antibiotics: Technologies and Global Markets
Report Highlights
The global antibiotics market reached $40.4 billion in 2022 and should reach $49.6 billion by 2027, with a compound annual growth rate (CAGR) of 4.2% during the forecast period of 2022-2027.
Report Includes
- 22 data tables and 16 additional tables
- An overview of the global market for antibiotics within the pharmaceutical industry
- Analyses of the global market trends, with data corresponding to market size for 2019-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
- Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user, and geographical region
- Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
- Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
- Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc. and Sanofi
Report Scope
This report is focused on newer drugs and innovations in chemical compounds, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control, drugs used for symptomatic treatment and not for the elimination of the virus from the host and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potential of antibiotics with detailed analysis of the competitive environment. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment are covered, along with a market projection for 2027 and market share assessment for key players.
The report segments the market for antibiotics based on product type, route of administration, application and geographical region. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA and other inhibitors (RNA, mycolic acid, folic acid). Based on route of administration, the market is segmented into oral and topical.
By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa. Detailed analysis of major countries (U.S., Germany, UK, Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa) will be covered in the regional segment. For market estimates, data will be provided for 2021 as the base year, with estimates for 2022 and forecast value for 2027.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
|---|---|
| Base year considered | 2021 |
| Forecast period considered | 2022-2027 |
| Base year market size | $39.1 billion |
| Market size forecast | $49.6 billion |
| Growth rate | CAGR of 4.2% for the forecast period of 2022-2027 |
| Units considered | $ Millions |
| Segments covered | Product, Route of Administration |
| Regions covered | North America, Europe, Asia-Pacific, Latin America, Middle East and Africa |
| Countries covered | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia, Japan, China, India, Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Korea, Indonesia, Brazil, Argentina, Chile, Colombia, Peru, GCC countries, South Africa, Tukey, Egypt, Nigeria, Kenya |
| Key Market Drivers |
|
| Companies studied | ABBOTT , F. HOFFMANN-LA ROCHE AG , GLAXOSMITHKLINE PLC , JOHNSON & JOHNSON , MERCK & CO. INC. , PFIZER INC. , SANOFI , VIATRIS INC. |
Report Highlights
The global market for antibiotics should grow from $44.4 billion in 2020 to reach $65.4 billion by 2025 at a compound annual growth rate (CAGR) of 8.1% during the period of 2020-2025.
Report Includes
- 28 data tables and 16 additional tables
- Comprehensive overview of the global market for antibiotics within the pharmaceutical industry
- Analyses of the global market trends, with data corresponding to market size for 2018-2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Latest information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
- Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user and geographical region
- Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
- Impact of COVID-19 on the pharmaceutical market for antibiotics and an outlook of short-term vs. long-term impacts of COVID-19 pandemic
- Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
- Detailed company profiles of the major global corporations, including Abbott, F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Sanofi
Report Highlights
The global systemic antibiotics market should reach nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.
Report Includes
- An overview of the global markets and related technologies for antibiotics.
- Analyses of global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Breakdowns of the market by human application and veterinary application
- A look at major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets
- Profiles of key players in the market and analysis of their core competencies and market shares
- Detailed coverage of
- Beta–lactams.
- Penicillin.
- Cephalosporins.
- Carbapenems.
- Fluoroquinolones.
- Second generation.
- Third generation.
- Others.
- Macrolides.
- Tetracycline.
- Other antibiotic classes.
Report Highlights
The global systemic antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%.
Report Includes
- An overview of the global market for systemic antibiotics.
- Analyses of global market trends, with data from 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Details on the factors most impacting the market, including major market growth inhibitors and catalysts.
- Discussion on important trends and products.
- Comprehensive profiles of leading companies in the industry.
Report Highlights
- Overall sales in the current antibiotics and new products market were nearly $40 billion in 2008. It increased to $41.5 billion in 2009. By 2014, it is projected to increase to $65.5 billion, for a 5-year compound annual growth rate (CAGR) of 9.6%.
- The largest segment antibiotic drugs market was nearly $36 billion in 2008; this further increased to $37 billion in 2009, this projected to reach $50 billion in 2014, for a 5-year CAGR of 5.9%.
- Sales in the bacterial vaccines market amounted to $3.6 billion in 2008 which increased slightly to $3.9 billion in 2009. This is projected to increase to $15 billion in 2014, for a 5-year CAGR of 31.6%.
Report Highlights
- Worldwide, the total market for new and currently available antibiotics reached $22.3 billion in 2001. Average annual growth rate (AAGR) of 9.1%, this market will climb to $34.5 billion in 2006.
- Growth will be driven by new products, whose sales will rise at an AAGR of more than 50% to $7.4 billion in 2006, representing 21% of the total market.
- Sales in 2001 were just under $1 billion, just 4% of the market.
- In 2001, the market for currently available antibiotics was $21.3 billion and is projected to increase at an AAGR of only 4.9% to $27.2 billion by 2006.
- From 2001 to 2006, some 40 new products or formulations could be introduced into the antibiotics sector.
- Many of these drugs will likely prove effective against infectious disease organisms that have developed multidrug resistances, rejuvenating the antibiotics market.